Deok-Bog Moon1, Sung-Gyu Lee, Shin Hwang. 1. Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Abstract
BACKGROUNDS/AIMS: Hepatic resection (HR) has been the standard therapy for patients with small hepatocellular carcinoma (HCC) with preserved liver function in Child A cirrhosis. However, the underlying cirrhosis is responsible for high recurrence and long-term complications of portal hypertension and liver failure. Currently, liver transplantation (LT) has proven to be a good alternative to HR. We studied to determine whether LT could be an alternative initial therapy or not in HCC patients with less than 3 cm-sized, single nodule with Child A cirrhosis. METHODS: From January 1995 to December 2005, there were 100 HR and 17 LT (living donor LT 15, deceased donor LT 2) patients. Clinicopathologic characteristics were reviewed and survival rates between LT and HR groups were compared. The applicability of salvage LT at the time of recurrence was also evaluated. RESULTS: There was no difference in age, sex, etiology and in-hospital mortality between the two groups. LTs were not performed for the patients with preserved liver function, that is, BCLC stage A1. Most initial recurrences after HR occurred in liver (37/39), but only one recurrence after LT occurred in lung. Overall survival differences between LT and HR were not significant. However, disease-free survival after LT and HR were significantly different (p = 0.047). Potential candidates for salvage LT were 37 patients including hepatic failure (n = 10), and its applicability on recurrence was 69.2% (27/39). CONCLUSION: HR is still a good option for the selected patients because of lower cost and no requirement of donors. However, primary LT can be a treatment of choice for single, small HCC of Child A cirrhosis in the presence of portal hypertension because of excellent disease-free survival. (c) 2007 S. Karger AG, Basel.
BACKGROUNDS/AIMS: Hepatic resection (HR) has been the standard therapy for patients with small hepatocellular carcinoma (HCC) with preserved liver function in ChildA cirrhosis. However, the underlying cirrhosis is responsible for high recurrence and long-term complications of portal hypertension and liver failure. Currently, liver transplantation (LT) has proven to be a good alternative to HR. We studied to determine whether LT could be an alternative initial therapy or not in HCC patients with less than 3 cm-sized, single nodule with ChildA cirrhosis. METHODS: From January 1995 to December 2005, there were 100 HR and 17 LT (living donor LT 15, deceased donor LT 2) patients. Clinicopathologic characteristics were reviewed and survival rates between LT and HR groups were compared. The applicability of salvage LT at the time of recurrence was also evaluated. RESULTS: There was no difference in age, sex, etiology and in-hospital mortality between the two groups. LTs were not performed for the patients with preserved liver function, that is, BCLC stage A1. Most initial recurrences after HR occurred in liver (37/39), but only one recurrence after LT occurred in lung. Overall survival differences between LT and HR were not significant. However, disease-free survival after LT and HR were significantly different (p = 0.047). Potential candidates for salvage LT were 37 patients including hepatic failure (n = 10), and its applicability on recurrence was 69.2% (27/39). CONCLUSION: HR is still a good option for the selected patients because of lower cost and no requirement of donors. However, primary LT can be a treatment of choice for single, small HCC of ChildA cirrhosis in the presence of portal hypertension because of excellent disease-free survival. (c) 2007 S. Karger AG, Basel.
Authors: Markus B Schoenberg; Julian N Bucher; Adrian Vater; Alexandr V Bazhin; Jingcheng Hao; Markus O Guba; Martin K Angele; Jens Werner; Markus Rentsch Journal: Dtsch Arztebl Int Date: 2017-08-07 Impact factor: 5.594
Authors: Jin Hean Koh; Darren Jun Hao Tan; Yuki Ong; Wen Hui Lim; Cheng Han Ng; Phoebe Wen Lin Tay; Jie Ning Yong; Mark D Muthiah; Eunice X Tan; Ning Qi Pang; Beom Kyung Kim; Nicholas Syn; Alfred Kow; Brian K P Goh; Daniel Q Huang Journal: Hepatobiliary Surg Nutr Date: 2022-02 Impact factor: 8.265
Authors: Wing Chiu Dai; See Ching Chan; Kenneth S H Chok; Tan To Cheung; William W Sharr; Albert C Y Chan; Simon H Y Tsang; James Y Y Fung; Ronnie T P Poon; Sheung Tat Fan; Chung Mau Lo Journal: HPB (Oxford) Date: 2014-01-28 Impact factor: 3.647
Authors: Ramanathan M Seshadri; Siddesh Besur; David J Niemeyer; Megan Templin; Iain H McKillop; Ryan Z Swan; John B Martinie; Mark W Russo; David A Iannitti Journal: HPB (Oxford) Date: 2014-06-25 Impact factor: 3.647
Authors: See Ching Chan; Sheung Tat Fan; Kenneth S H Chok; Tan To Cheung; Albert C Y Chan; James Y Y Fung; Ronnie T P Poon; Chung Mau Lo Journal: Hepatol Int Date: 2011-10-21 Impact factor: 6.047